Senseonics Holdings, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for August 8, 2024 at 4:30 P.M. Eastern Time
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring (CGM) systems for diabetes patients, has announced its schedule for the second quarter 2024 earnings release and conference call. The financial results will be released after market close on Thursday, August 8, 2024. A conference call to review the Q2 2024 performance will be held at 4:30 p.m. Eastern Time on the same day.
The call will be simultaneously webcast and accessible via the company's website. Investors can join the conference call by dialing 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International) with passcode 4740206.
Senseonics Holdings (NYSE American: SENS), un'azienda tecnologica medica specializzata in sistemi di monitoraggio continuo della glicemia (CGM) impiantabili a lungo termine per pazienti diabetici, ha annunciato il programma per il rilascio dei risultati finanziari del secondo trimestre 2024 e la teleconferenza. I risultati finanziari verranno pubblicati dopo la chiusura del mercato giovedì 8 agosto 2024. Una teleconferenza per rivedere le performance del secondo trimestre 2024 si terrà alle 16:30 ora orientale dello stesso giorno.
La chiamata sarà trasmessa in diretta streaming e accessibile tramite il sito web dell'azienda. Gli investitori possono partecipare alla teleconferenza componendo il numero 1-888-317-6003 (US/Canada) oppure 1-412-317-6061 (Internazionale) utilizzando il codice di accesso 4740206.
Senseonics Holdings (NYSE American: SENS), una compañía de tecnología médica especializada en sistemas de monitoreo continuo de glucosa (CGM) implantables a largo plazo para pacientes con diabetes, ha anunciado su calendario para el informe de ganancias del segundo trimestre de 2024 y la llamada de conferencia. Los resultados financieros se publicarán después del cierre del mercado el jueves 8 de agosto de 2024. Se llevará a cabo una llamada de conferencia para revisar el rendimiento del segundo trimestre de 2024 a las 4:30 p. m. hora del Este el mismo día.
La llamada se transmitirá simultáneamente en la web y será accesible a través del sitio web de la compañía. Los inversores pueden unirse a la llamada de conferencia marcando el 1-888-317-6003 (EE. UU./Canadá) o 1-412-317-6061 (Internacional) con el código de acceso 4740206.
센세오닉스 홀딩스(뉴욕증권거래소 미국: SENS)는 당뇨병 환자를 위한 장기 이식 가능한 지속적인 혈당 모니터링(CGM) 시스템을 전문으로 하는 의료 기술 회사로, 2024년 2분기 실적 발표 및 전화 회의 일정이 발표되었다. 재무 결과는 2024년 8월 8일 목요일 장 마감 후에 발표된다. Q2 2024 성과를 검토하기 위한 전화 회의는 같은 날 동부 표준시 기준 오후 4시 30분에 개최될 예정이다.
이 통화는 동시에 웹캐스트 형식으로 진행되며 회사 웹사이트를 통해 접근할 수 있다. 투자자들은 1-888-317-6003 (미국/캐나다) 또는 1-412-317-6061 (국제)으로 전화하여 접속 코드 4740206을 사용하여 회의에 참여할 수 있다.
Senseonics Holdings (NYSE American: SENS), une entreprise de technologie médicale spécialisée dans les systèmes de surveillance continue de la glycémie (CGM) implantables à long terme pour les patients diabétiques, a annoncé son calendrier pour le communiqué de résultats du deuxième trimestre 2024 et la conférence téléphonique. Les résultats financiers seront publiés après la fermeture du marché le jeudi 8 août 2024. Une conférence téléphonique pour examiner les performances du 2e trimestre 2024 aura lieu le même jour à 16h30, heure de l'Est.
La conférence sera diffusée en simultané et accessible via le site Web de l'entreprise. Les investisseurs peuvent rejoindre la conférence téléphonique en composant le 1-888-317-6003 (États-Unis/Canada) ou le 1-412-317-6061 (International) avec le code d'accès 4740206.
Senseonics Holdings (NYSE American: SENS), ein Medizintechnikunternehmen, das sich auf langfristige, implantierbare Systeme zur kontinuierlichen Blutzuckermessung (CGM) für Diabetiker spezialisiert hat, hat seinen Zeitplan für die Gewinnveröffentlichung des 2. Quartals 2024 und die Telefonkonferenz bekannt gegeben. Die finanziellen Ergebnisse werden nach Börsenschluss am Donnerstag, den 8. August 2024 veröffentlicht. Eine Telefonkonferenz zur Überprüfung der Leistungen des 2. Quartals 2024 findet am selben Tag um 16:30 Uhr Eastern Time statt.
Der Anruf wird gleichzeitig als Webcast übertragen und ist über die Website des Unternehmens zugänglich. Investoren können an der Telefonkonferenz teilnehmen, indem sie 1-888-317-6003 (USA/Kanada) oder 1-412-317-6061 (international) anrufen und den Zugangscode 4740206 verwenden.
- None.
- None.
Management will hold a conference call to review the Company’s second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725653828/en/
Investor Contact
Philip Taylor
Gilmartin Group
415-937-5406
Investors@senseonics.com
Source: Senseonics Holdings, Inc.
FAQ
When will Senseonics Holdings (SENS) release its Q2 2024 earnings?
What time is the Senseonics Holdings (SENS) Q2 2024 earnings conference call?
How can investors access the Senseonics Holdings (SENS) Q2 2024 earnings call?
Where can I find the webcast link for Senseonics Holdings (SENS) Q2 2024 earnings call?
